TRACKING PROGRESS TO ADDRESS AMR, January 2018 – AMR Industry Alliance Progress Report- January2018
Bacterial infections remain a serious threat to humanity. The increasing impact of antimicrobial resistance is projected to create a global crisis totaling 10 million deaths per year in 2050. To combat this, we will focus on developing vaccines against gram negative bacteria by our R&D platforms.
The initial project within our proprietary mOMV technologies will be a second generation meningococcal vaccine. This product will be developed with the purpose of eradicating the infection in the African meningitis belt, a region of sub-Saharan Africa where the incidence rate of meningitis is very high, primarily due to Neisseria meningitis.